logo

NKTR

Nektar Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 1
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Revenue Beats Expectation
Revenue Keeps Dropping

Key Stats

0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000

About NKTR

Nektar Therapeutics

A biopharmaceutical company that developing investigational medicines in oncology, immunology, and inflammatory diseases

Pharmaceutical
Invalid Date
05/06/1994
NASDAQ Stock Exchange
61
12-31
Common stock
455 Mission Bay Boulevard South, San Francisco, California 94158
--
Nektar Therapeutics was founded in California in 1990 and re-registered in Delaware in 1998. The company is a clinical-stage, investigational drug discovery biopharmaceutical company focused on the discovery and development of innovative drugs in the field of immunotherapy. In this growing field, the company is committed to creating new immunomodulators that selectively induce, amplify, attenuate or block immune responses to achieve the desired therapeutic effect.

Earnings Call

Company Financials

EPS

NKTR has released its 2025 Q1 earnings. EPS was reported at -0.24, versus the expected -0.19, missing expectations. The chart below visualizes how NKTR has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

NKTR has released its 2025 Q1 earnings report, with revenue of 10.46M, reflecting a YoY change of -51.66%, and net profit of -50.88M, showing a YoY change of -38.26%. The Sankey diagram below clearly presents NKTR's revenue sources and cost distribution.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime